AGEN

SEC source: 0001193125-26-412039 · ownership.xml · nonDerivative · entry 1

HARRISON THOMAS L · CIK 0001247340 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,988

F1 · security: Acquired under the Agenus Inc. Board Compensation Election Policy pursuant to which a director may elect to receive their director fees in shares of Agenus' common stock.

F2 · price: 6.893 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such shares were issued.

SEC source: 0001193125-26-412050 · ownership.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,807.791

Underlying: Common Stock · 1,178.764 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $6.893 per Deferred Stock Unit acquired on October 1, 2026. The price of each Deferred Stock Unit acquired on October 1, 2026 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0001193125-26-347517 · ownership.xml · derivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,971,500

Underlying: Common Stock · 1,971,500 shares

Expires 2036-08-10

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. Amended and Restated 2019 Equity Incentive Plan. The options are divided into five equal tranches, each of which vests only if the Company's stock price achieves and sustains, for 30 consecutive calendar days during the five-year performance period, a level equal to 3x, 4x, 5x, 6x, and 8x, respectively, of the measurement price of $7.78 per share, subject in each case to a minimum three-year service requirement.

SEC source: 0001193125-26-392937 · ownership.xml · derivative · entry 1

Marcucci Marco Tullio · CIK 0002153981 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2036-08-05

F1 · derivative.exercise_date: Option awarded in connection with Mr. Marcucci's appointment to the Board of Directors, vesting in three equal annual installments commencing on the first anniversary of the date of grant, subject to continued service.

SEC source: 0001193125-26-340007 · ownership.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-08-05

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vest over three (3) years, with one-third (1/3) vesting on the first anniversary of the Grant Date and the remaining two-thirds (2/3) vesting in two equal annual installments thereafter.

SEC source: 0001193125-26-339996 · ownership.xml · derivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2036-08-05

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vest over three (3) years, with one-third (1/3) vesting on the first anniversary of the Grant Date and the remaining two-thirds (2/3) vesting in two equal annual installments thereafter.

SEC source: 0001193125-26-339968 · ownership.xml · derivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-08-05

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vest over three (3) years, with one-third (1/3) vesting on the first anniversary of the Grant Date and the remaining two-thirds (2/3) vesting in two equal annual installments thereafter.

SEC source: 0001193125-26-339949 · ownership.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2036-08-05

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vest over three (3) years, with one-third (1/3) vesting on the first anniversary of the Grant Date and the remaining two-thirds (2/3) vesting in two equal annual installments thereafter.

SEC source: 0001193125-26-344617 · ownership.xml · derivative · entry 1

HARRISON THOMAS L · CIK 0001247340 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2036-08-05

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vest over three (3) years, with one-third (1/3) vesting on the first anniversary of the Grant Date and the remaining two-thirds (2/3) vesting in two equal annual installments thereafter.

SEC source: 0001193125-26-344599 · ownership.xml · derivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2036-08-05

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vest over three (3) years, with one-third (1/3) vesting on the first anniversary of the Grant Date and the remaining two-thirds (2/3) vesting in two equal annual installments thereafter.

SEC source: 0001193125-26-303047 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 371,108

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending July 10th, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.35 is the closing price of our Common Stock on July 10th, 2026, the last trading day for the payroll date for the pay period ending July 10th, 2026.

SEC source: 0001193125-26-297094 · ownership.xml · nonDerivative · entry 1

HARRISON THOMAS L · CIK 0001247340 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,545

F1 · security: Acquired under the Agenus Inc. Board Compensation Election Policy pursuant to which a director may elect to receive their director fees in shares of Agenus' common stock.

F2 · price: $3.583 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such shares were issued.

SEC source: 0001193125-26-297088 · ownership.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,180.771

Underlying: Common Stock · 2,267.765 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.583 per Deferred Stock Unit acquired on July 1, 2026. The price of each Deferred Stock Unit acquired on July 1, 2026 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0001193125-26-289278 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 366,256

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 26th, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.03 is the closing price of our Common Stock on June 26th, 2026, the last trading day for the payroll date for the pay period ending June 26th, 2026.

SEC source: 0001193125-26-271889 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 360,892

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 12th, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.30 is the closing price of our Common Stock on June 12th, 2026, the last trading day for the payroll date for the pay period ending June 12th, 2026.

SEC source: 0001193125-26-252375 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 355,967

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 29, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.50 is the closing price of our Common Stock on May 29, 2026, the last trading day for the payroll date for the pay period ending May 29, 2026.

SEC source: 0001193125-26-231046 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,323

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 15, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.58 is the closing price of our Common Stock on May 15, 2026, the last trading day for the payroll date for the pay period ending May 15, 2026.

SEC source: 0001193125-26-206908 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 346,783

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending May 1, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.84 is the closing price of our Common Stock on May 1, 2026, the last trading day for the payroll date for the pay period ending May 1, 2026.

SEC source: 0001193125-26-187079 · ownership.xml · derivative · entry 3

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,550

Underlying: Common Stock · 137,550 shares

Expires 2036-04-24

F2 · derivative.exercise_date: Option awarded in lieu of the 2025 annual cash bonus and in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. Vests in full on May 24, 2026.

SEC source: 0001193125-26-187079 · ownership.xml · derivative · entry 2

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,750

Underlying: Common Stock · 27,750 shares

Expires 2036-04-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027, and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001193125-26-187079 · ownership.xml · derivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,000,000

Underlying: Common Stock · 1,000,000 shares

Expires 2036-04-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027, and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001193125-26-187090 · ownership.xml · derivative · entry 1

Hirsch Susan B · CIK 0001827663 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2036-04-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests on the one-year anniversary of the grant date.

SEC source: 0001193125-26-187085 · ownership.xml · derivative · entry 2

Buell Jennifer · CIK 0001711184 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2036-04-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027 and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001193125-26-187085 · ownership.xml · derivative · entry 1

Buell Jennifer · CIK 0001711184 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2036-04-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027 and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001193125-26-187083 · ownership.xml · derivative · entry 2

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,333

Underlying: Common Stock · 95,333 shares

Expires 2036-04-24

F2 · derivative.exercise_date: Option awarded in lieu of the 2025 annual cash bonus and in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. Vests in full on May 24, 2026.

SEC source: 0001193125-26-187083 · ownership.xml · derivative · entry 1

O'Day Steven J · CIK 0001845281 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2036-04-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027, and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001193125-26-187082 · ownership.xml · derivative · entry 1

HARRISON THOMAS L · CIK 0001247340 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,500

Underlying: Common Stock · 122,500 shares

Expires 2036-04-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests on the one-year anniversary of the grant date.

SEC source: 0001193125-26-187081 · ownership.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2036-04-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests on the one-year anniversary of the grant date.

SEC source: 0001193125-26-187080 · ownership.xml · derivative · entry 2

Charette Austin · CIK 0002105444 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,619

Underlying: Common Stock · 17,619 shares

Expires 2036-04-24

F2 · derivative.exercise_date: Option awarded in lieu of the 2025 annual cash bonus and in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. Vests in full on May 24, 2026.

SEC source: 0001193125-26-187080 · ownership.xml · derivative · entry 1

Charette Austin · CIK 0002105444 · Principal Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2036-04-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027, and the balance vesting in equal quarterly installments thereafter.

SEC source: 0001193125-26-187078 · ownership.xml · derivative · entry 1

Corvese Brian · CIK 0001393207 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,000

Underlying: Common Stock · 210,000 shares

Expires 2036-04-24

F1 · derivative.exercise_date: Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests on the one-year anniversary of the grant date.

SEC source: 0001193125-26-166818 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 342,550

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 17, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.79 is the closing price of our Common Stock on April 17, 2026, the last trading day for the payroll date for the pay period ending April 17, 2026.

SEC source: 0001193125-26-143765 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 339,147

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 3, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.33 is the closing price of our Common Stock on April 2, 2026, the last trading day for the payroll date for the pay period ending April 3, 2026.

SEC source: 0001193125-26-140270 · ownership.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,361.262

Underlying: Common Stock · 2,448.256 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.319 per Deferred Stock Unit acquired on April 1, 2026. The price of each Deferred Stock Unit acquired on April 1, 2026 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0001193125-26-152886 · ownership.xml · nonDerivative · entry 1

HARRISON THOMAS L · CIK 0001247340 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,998

F1 · security: Acquired under the Agenus Inc. Board Compensation Election Policy pursuant to which a director may elect to receive their director fees in shares of Agenus' common stock.

F2 · price: $3.319 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such shares were issued.

SEC source: 0001193125-26-121840 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 334,518

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 20, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.71 is the closing price of our Common Stock on March 20, 2026, the last trading day for the payroll date for the pay period ending March 20, 2026.

SEC source: 0001193125-26-098528 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 330,535

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending March 6, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $2.96 is the closing price of our Common Stock on March 6, 2026, the last trading day for the payroll date for the pay period ending March 6, 2026.

SEC source: 0001193125-26-066948 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 325,541

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending February 20, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.06 is the closing price of our Common Stock on February 20, 2026, the last trading day for the payroll date for the pay period ending February 20, 2026.

SEC source: 0001193125-26-042772 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,712

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending February 6, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $2.94 is the closing price of our Common Stock on February 6, 2026, the last trading day for the payroll date for the pay period ending February 6, 2026.

SEC source: 0001193125-26-022561 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 315,685

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending January 23, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.24 is the closing price of our Common Stock on January 23, 2026, the last trading day for the payroll date for the pay period ending January 23, 2026.

SEC source: 0001193125-26-010360 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 311,123

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending January 9, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.91 is the closing price of our Common Stock on January 9, 2026, the last trading day for the payroll date for the pay period ending January 9, 2026.

SEC source: 0001193125-26-002395 · ownership.xml · nonDerivative · entry 1

HARRISON THOMAS L · CIK 0001247340 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,770

F1 · security: Acquired under the Agenus Inc. Board Compensation Election Policy pursuant to which a director may elect to receive their director fees in shares of Ageuns' common stock.

F2 · price: $3.982 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such shares were issued.

SEC source: 0001193125-26-002391 · ownership.xml · derivative · entry 1

Wright Timothy · CIK 0001383313 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,913.006

Underlying: Common Stock · 2,040.576 shares

Expires not disclosed

F1 · derivative.exercise_price: Deferred Stock Units convert to shares of Common Stock on a 1 for 1 basis.

F3 · price: $3.982 per Deferred Stock Unit acquired on January 2, 2026. The price of each Deferred Stock Unit acquired on January 2, 2026 is the average of the closing price for the Company's common stock for all trading days during the calendar quarter immediately preceding the date such Deferred Stock Unit was acquired pursuant to the Plan.

F2 · derivative.exercise_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

F2 · derivative.expiration_date: Acquired under the Agenus Inc. Amended and Restated Directors' Deferred Compensation Plan, as amended (the "Plan"). Deferred Stock Units represent an equal amount of the Company's common stock to be distributed under the terms of the Plan, typically once the director ceases to serve as a director of the Company.

SEC source: 0001193125-25-335288 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 307,343

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending December 26, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.31 is the closing price of our Common Stock on December 26, 2025, the last trading day for the payroll date for the pay period ending December 26, 2025.

SEC source: 0001193125-25-319186 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 302,401

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending December 12, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.79 is the closing price of our Common Stock on December 12, 2025, the last trading day for the payroll date for the pay period ending December 12, 2025.

SEC source: 0001193125-25-303859 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 298,085

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending November 28, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.56 is the closing price of our Common Stock on November 28, 2025, the last trading day for the payroll date for the pay period ending November 28, 2025.

SEC source: 0001193125-25-284600 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 294,498

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending November 14, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.34 is the closing price of our Common Stock on November 14, 2025, the last trading day for the payroll date for the pay period ending November 14, 2025.

SEC source: 0001193125-25-266875 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 290,729

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending October 31, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.97 is the closing price of our Common Stock on October 31, 2025, the last trading day for the payroll date for the pay period ending October 31, 2025.

SEC source: 0001193125-25-245089 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 286,609

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending October 17, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $3.88 is the closing price of our Common Stock on October 17, 2025, the last trading day for the payroll date for the pay period ending October 17, 2025.

SEC source: 0001193125-25-231857 · ownership.xml · nonDerivative · entry 1

ARMEN GARO H · CIK 0000935679 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 282,393

F1 · security: At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending October 3, 2025. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.

F2 · price: $4.14 is the closing price of our Common Stock on October 3, 2025, the last trading day for the payroll date for the pay period ending October 3, 2025.